AR065453A1 - Producto farmaceutico y metodo de tratamiento - Google Patents
Producto farmaceutico y metodo de tratamientoInfo
- Publication number
- AR065453A1 AR065453A1 ARP080100757A ARP080100757A AR065453A1 AR 065453 A1 AR065453 A1 AR 065453A1 AR P080100757 A ARP080100757 A AR P080100757A AR P080100757 A ARP080100757 A AR P080100757A AR 065453 A1 AR065453 A1 AR 065453A1
- Authority
- AR
- Argentina
- Prior art keywords
- chloro
- spiro
- benzofuran
- piperidin
- oxy
- Prior art date
Links
- 239000000825 pharmaceutical preparation Substances 0.000 title abstract 5
- 229940127557 pharmaceutical product Drugs 0.000 title abstract 5
- -1 cyano, hydroxyl Chemical group 0.000 abstract 14
- 150000003839 salts Chemical group 0.000 abstract 10
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 abstract 9
- 239000001257 hydrogen Substances 0.000 abstract 7
- 229910052739 hydrogen Inorganic materials 0.000 abstract 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 7
- ZELCJNKQCKIECO-UHFFFAOYSA-N spiro[3h-1-benzofuran-2,4'-piperidine] Chemical compound C1C2=CC=CC=C2OC11CCNCC1 ZELCJNKQCKIECO-UHFFFAOYSA-N 0.000 abstract 6
- 239000002253 acid Substances 0.000 abstract 5
- VFRSADQPWYCXDG-LEUCUCNGSA-N ethyl (2s,5s)-5-methylpyrrolidine-2-carboxylate;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CCOC(=O)[C@@H]1CC[C@H](C)N1 VFRSADQPWYCXDG-LEUCUCNGSA-N 0.000 abstract 5
- 229910052736 halogen Inorganic materials 0.000 abstract 4
- 150000002367 halogens Chemical group 0.000 abstract 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 4
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 abstract 3
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 abstract 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 3
- 125000003003 spiro group Chemical group 0.000 abstract 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N triethylamine Natural products CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 abstract 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- JFUAWXPBHXKZGA-IBGZPJMESA-N 4-fluoro-2-[(4r)-5,5,5-trifluoro-4-hydroxy-2-methyl-4-(1h-pyrrolo[2,3-c]pyridin-2-ylmethyl)pentan-2-yl]phenol Chemical compound C([C@@](O)(CC=1NC2=CN=CC=C2C=1)C(F)(F)F)C(C)(C)C1=CC(F)=CC=C1O JFUAWXPBHXKZGA-IBGZPJMESA-N 0.000 abstract 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N EtOH Substances CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 2
- 229940124748 beta 2 agonist Drugs 0.000 abstract 2
- 239000004202 carbamide Substances 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 229940124750 glucocorticoid receptor agonist Drugs 0.000 abstract 2
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 abstract 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 abstract 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 abstract 1
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 abstract 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 1
- URVPWPSIVXZUQG-SFHVURJKSA-N 2-[(2s)-3-(6-chlorospiro[1h-2-benzofuran-3,4'-piperidine]-1'-yl)-2-hydroxypropoxy]-4-hydroxy-n-methylbenzamide Chemical compound CNC(=O)C1=CC=C(O)C=C1OC[C@@H](O)CN1CCC2(C3=CC=C(Cl)C=C3CO2)CC1 URVPWPSIVXZUQG-SFHVURJKSA-N 0.000 abstract 1
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 abstract 1
- VKDNYQKDAXLFIL-UHFFFAOYSA-N 4-hydroxy-n-methylbenzamide Chemical compound CNC(=O)C1=CC=C(O)C=C1 VKDNYQKDAXLFIL-UHFFFAOYSA-N 0.000 abstract 1
- XTIHQPFHDYMPLI-INIZCTEOSA-N 5-chloro-2-[(2s)-3-(5-chlorospiro[3h-1-benzofuran-2,4'-piperidine]-1'-yl)-2-hydroxypropoxy]-4-(2,2-difluoroethoxy)benzoic acid Chemical compound C([C@@H](O)CN1CCC2(OC3=CC=C(Cl)C=C3C2)CC1)OC1=CC(OCC(F)F)=C(Cl)C=C1C(O)=O XTIHQPFHDYMPLI-INIZCTEOSA-N 0.000 abstract 1
- 125000003341 7 membered heterocyclic group Chemical group 0.000 abstract 1
- OSNANICDBBZIMG-IBGZPJMESA-N 7-[(1r)-2-[2-[3-[2-(2-chlorophenyl)ethylamino]propylsulfanyl]ethylamino]-1-hydroxyethyl]-4-hydroxy-3h-1,3-benzothiazol-2-one Chemical compound C([C@H](O)C=1C=2SC(=O)NC=2C(O)=CC=1)NCCSCCCNCCC1=CC=CC=C1Cl OSNANICDBBZIMG-IBGZPJMESA-N 0.000 abstract 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 abstract 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 abstract 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- XCUAIINAJCDIPM-XVFCMESISA-N N(4)-hydroxycytidine Chemical group O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=NO)C=C1 XCUAIINAJCDIPM-XVFCMESISA-N 0.000 abstract 1
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical class OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical group [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 abstract 1
- 229960004436 budesonide Drugs 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 abstract 1
- 229960002848 formoterol Drugs 0.000 abstract 1
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 abstract 1
- 229960004078 indacaterol Drugs 0.000 abstract 1
- QZZUEBNBZAPZLX-QFIPXVFZSA-N indacaterol Chemical compound N1C(=O)C=CC2=C1C(O)=CC=C2[C@@H](O)CNC1CC(C=C(C(=C2)CC)CC)=C2C1 QZZUEBNBZAPZLX-QFIPXVFZSA-N 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- ZVULMJYRVAVKCP-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-n-[2-[2-(4-hydroxy-2-oxo-3h-1,3-benzothiazol-7-yl)ethylamino]ethyl]-3-(2-naphthalen-1-ylethoxy)propanamide Chemical compound C1=CC=C2C(CCOCCC(=O)N(CCNCCC=3C=4SC(=O)NC=4C(O)=CC=3)CCN(CC)CC)=CC=CC2=C1 ZVULMJYRVAVKCP-UHFFFAOYSA-N 0.000 abstract 1
- PRCGNNOLGSGSJZ-KRWDZBQOSA-N n-[2-[(2s)-3-(5-chlorospiro[1,3-benzodioxole-2,4'-piperidine]-1'-yl)-2-hydroxypropoxy]-4-hydroxyphenyl]acetamide Chemical compound CC(=O)NC1=CC=C(O)C=C1OC[C@@H](O)CN1CCC2(OC3=CC(Cl)=CC=C3O2)CC1 PRCGNNOLGSGSJZ-KRWDZBQOSA-N 0.000 abstract 1
- JWMBFLXRBZIVNF-IBGZPJMESA-N n-[2-[(2s)-3-(5-chlorospiro[3h-1-benzofuran-2,4'-piperidine]-1'-yl)-2-hydroxypropoxy]-4-hydroxyphenyl]acetamide Chemical compound CC(=O)NC1=CC=C(O)C=C1OC[C@@H](O)CN1CCC2(OC3=CC=C(Cl)C=C3C2)CC1 JWMBFLXRBZIVNF-IBGZPJMESA-N 0.000 abstract 1
- DHMMQCJCZXAHQH-IBGZPJMESA-N n-[2-[(2s)-3-(5-fluorospiro[3h-1-benzofuran-2,4'-piperidine]-1'-yl)-2-hydroxypropoxy]-4-hydroxyphenyl]acetamide Chemical compound CC(=O)NC1=CC=C(O)C=C1OC[C@@H](O)CN1CCC2(OC3=CC=C(F)C=C3C2)CC1 DHMMQCJCZXAHQH-IBGZPJMESA-N 0.000 abstract 1
- MIMFGHFRAWVGAZ-KRWDZBQOSA-N n-[5-chloro-2-[(2s)-3-(5-chlorospiro[3h-1-benzofuran-2,4'-piperidine]-1'-yl)-2-hydroxypropoxy]-4-hydroxyphenyl]acetamide Chemical compound CC(=O)NC1=CC(Cl)=C(O)C=C1OC[C@@H](O)CN1CCC2(OC3=CC=C(Cl)C=C3C2)CC1 MIMFGHFRAWVGAZ-KRWDZBQOSA-N 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 125000004043 oxo group Chemical group O=* 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 abstract 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 abstract 1
- 208000023504 respiratory system disease Diseases 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Composiciones farmacéuticas y métodos para tratar enfermedades de las vías respiratorias, en especial una enfermedad pulmonar obstructiva cronica (COPD) y asma, en mamíferos por administracion de dicha combinacion Reivindicacion 1: Un productofarmacéutico caracterizado porque comprende, en combinacion, (a) un primer ingrediente activo, que consiste en un compuesto de formula general (1): donde: m es 0, 1 o 2; R1 es halogeno, ciano o haloalquilo C1-6; X, Y y Z son independientemente unaunion, -O-, -NH-, CH2- o -C(O)-, con la condicion de que solo uno de X, Y y Z es una union, y con la condicion de que X y Y no deben ser de manera simultánea -O- o -C(O)-; n es 0, 1 o 2; R2 es =O o alquilo C1-6; q es 0 o 1; R3 es hidrogeno,hidroxilo o NH2; R8 es hidrogeno o alquilo C1-6; A es una union o alquilo C1-3; R4 es hidrogeno, hidroxilo, oxo, NHC(O)R10, C(O)NR11R12, COOR13 o SO3R13 es hidrogeno, halogeno, hidroxilo o alcoxi C1-6, opcionalmente sustituido con uno o mássustituyentes que se seleccionan independientemente entre halogeno, ciano, hidroxilo y carboxilo; t es 0, 1 o 2; es halogeno, ciano, C1-3alcoxi o haloalquilo C1-3; R10 es hidrogeno, alquilo C1-3, NR11R12 o OR13; R11 y R12 se seleccionanindependientemente entre hidrogeno, alquilo y cicloalquilo C3-7, o R11 y R12 junto con el átomo de nitrogeno al que están unidos forman un anillo heterocíclico de entre 4 y 7 miembros, el cual se puede sustituir opcionalmente con uno o más gruposhidroxilo; y R13 es hidrogeno o alquilo C1-3, o una sal del mismo aceptable para uso farmacéutico; y (b) un segundo ingrediente activo, que es un agonista del receptor de glucocorticoide; y opcionalmente (c) un tercer ingrediente activo, queconsiste en a beta2-agonista, con la condicion de que el agonista no se seleccione entre una N-[2-(Dietilamino)etil]-N-(2-{[2-(4-hidroxi-2-oxo-2,3-dihidro-1,3-benzotiazol-7-il)etil]amino}etil)-3-[2-(1-naftil)etoxi]propanamida o una sal de la misma,a N-[2-(Dietilamino)etil]-N-(2-{[2-(4-hidroxi-2-oxo-2,3-dihidro-1,3-benzotiazol-7-il)etil]amino}etil)-3-[2-(3-clorofenil)etoxi]propanamida o una sal de la misma, o a 7-[(1R)-2-({2-[(3-{[2-(2-Clorofenil)etil]amino}propil)tio]etil}amino)-1-hidroxietil}-4-hidroxi-1,3-benzotiazol-2(3H)-ona o una sal de la misma. Reivindicacion 3: El producto farmacéutico de acuerdo con la reivindicacion 1, caracterizado porque el compuesto de formula (1) se selecciona entre: N-(2-{[(2S)-3-(5-cloro-1'H,3H-espiro[1-benzofuran-2,4'-piperidin]-1'-il)-2-hidroxipropil]oxi}-4-hidroxifenil)acetamida; Sal trifluoroacetato de N-(2-{[(2S)-3-(5-cloro-1'H-espiro[1,3-benzodioxol-2,4'-piperidin]-1'-il)-2-hidroxipropil]oxi}-4-hidroxifenil)acetamida; saltrifluoroacetato de 2-{[(2S)-3-(5-cloro-1'H,3H-espiro[1-benzofuran-2,4'-piperidin]-1'-il)-2-hidroxipropil]oxi}-4-hidroxi-N-metilbenzamida; sal trifluoroacetato del ácido 2-{[(2S)-3-(5-cloro-1'H,3H-espiro[1-benzofuran-2,4'-piperidin]-1'-il)-2-hidroxipropil]oxi}-4-hidroxibenzoico; Sal trifluoroacetato de N-(2-{[(2S)-3-(5-cloro-1'H,3H-espiro[2-benzofuran-1,4-piperidin]-1'-il)-2-hidroxipropil]oxi}-4-hidroxifenil)acetamida; 2-{[(2S)-3-(5-cloro-1'H,3H-espiro[2-benzofuran-1,4'-piperidin]-1'-il)-2-hidroxipropil]oxi}-4-hidroxi-N-metilbenzamida; N-(2-{[(2S)-3-(5-fluoro-1'H,3H-espiro[1-benzofuran-2,4-piperidin]-1'-il)-2-hidroxipropil]oxi}-4-hidroxifenil)acetamida; 2-{[(2S)-3-(5-fluoro-1'H,3H-espiro[1-benzofuran-2,4'-piperidin]-1'-il)-2-hidroxipropil}oxi}-4-hidroxi-N-metilbenzamida; N-[2-({(2S)-3-[(2R)-5-cloro-1'H,3H-espiro[1-benzofuran-2,3-pirrolidin]-1'-il]-2-hidroxipropil}oxi-4-hidroxifenil]acetamida; Sal trifluoroacetato de N-(2-{[(2S)-3-(5-cloro-1'H,3H-espiro[1-benzofuran-2,4'-piperidin]-1'-il)-2-hidroxipropil]oxi}-4-hidroxifenil)urea; clorhidrato del ácido 4-fluoro-2-{[(2S)-3-(5-fluoro-1'H,3H-espiro[1-benzofuran-2,4'-piperidin]-1'-il)-2-hidroxipropil]oxi}benzoico; Sal trifluoroacetato de N-(2-{[(2S)-3-(5-cloro-1'H,3H-espiro[1-benzofuran-2,4'- piperidin]-1'-il)-2-hidroxipropil]oxi}-4-fluorofenil)urea; Sal bis(trifluoroacetato) de N-(2-{[(2S)-2-amino-3-(5-fluoro-1'H,3H-espiro[1-benzofuran-2,4'-piperidin]-1'-iI)propil]oxi}-4-hidroxifenil)acetamida; 2-[(2S)-3-(5-clorospiro[benzofuran-2(3H),4'-piperidin]-1'-il)-2-hidroxipropoxi]-benzaldehido; Espiro[benzofuran-2(3H),4'-piperidin]-1'-etanol, 5-cloro-alfa-[[2-(2-hidroxietil)fenoxi]metil]-, (alfaS)-; Espiro[benzofuran-2(3H),4'-piperidin]-1'-etanol, 5-cloro-alfa-[[2-(hidroximetil)fenoxi]metil]-, (alfaS)-; N-(2-{[(2S)-3-(5-cloro-1'H,3H-espiro[1-benzofuran-2,4'-piperidin]-1'-il)-2-hidroxipropil]oxi}-5-cloro-4-hidroxifenil)acetamida; ácido 2-Cloro-5-{[(2S)-3-(5-cloro-1'H,3H-espiro[1-benzofuran-2,4'-piperidin]-1'-iI)-2-hidroxipropil)oxi}-(4-{acetilamino}fenoxi)acético; ácido 5-{[(2S)-3-(5-Cloro-1'H,3H-espiro[1-benzofuran-2,4'-piperidin]-1'-il)-2-hidroxipropil]oxi}-(4-{acetilamino}fenoxi)acético; ácido {2-Cloro-5-{[(2S)-3-(5-cloro-1'H,3H-espiro[1-benzofuran-2,4'-piperidin]-1'-iI)-2-hidroxipropil]oxi}-4-[(metilamino)carbonil]fenoxi}acético; ácido 2-{2-Cloro-5-{((2S)-3-(5-cloro-1'H,3H-espiro[1-benzofuran-2,4'-piperidin]-1'-iI)-2-hidroxipropil]oxi}-4-[(metilamino)carbonil]fenoxi}-2-metilpropanoico; ácido (2-Cloro-5-{[(2S)-3-(5-cloro-1'H,3H-espiro[1-benzofuran-2,4'-piperidin]-1'-iI)-2-hidroxipropil]oxi}-4-{[(3S)-3-hidroxipirrolidin-1-iI]carbonil}fenoxi)acético; sal trifluoroacetato del ácido 5-Cloro-2-{[(2S)-3-(S-cloro-1'H,3H-espiro[1-benzofuran-2,4'-piperidin]-1'-il)-2-hidroxipropil]oxi}-4-(cianometoxi)benzoico; sal trifluoroacetato del ácido 2-{[(2S)-3-(5-cloro-1'H,3H-espiro[1-benzofuran-2,4'-piperidin]-1'-il)-2-hidroxipropil]oxi}-5-cloro-4-(2,2-difluoroetoxi)benzoico;sal trifluoroacetato del ácido 5-Cloro-2-{[(2S)-3-(5-cloro-1'H,3H-espiro[1-benzofuran-2,4'-piperidin]-1'-iI)-2-hidroxipropil]oxi}-4-(3,3,3-trifluoropropoxi)benzoico; Sal trifluoroacetato de N-(2-{3-[5-cloro-1'H,3H-espiro[1-benzofuran-2,4'-piperidin]-1'-il]propoxi}fenil)acetamida; Sal de ácido trifluoroacético y ácido metil 3-(2-{[(2S)-3-(5-cloro-1'H3H-espiro[1-benzofuran-2,4'-piperidin]-1'-il)-2-hidroxipropil]oxi}-4-fluorofenil) propanoico; N-(2-{[(2S)-3-({espiro[indol-2,4'-piperidin]-3(1H)-ona}-1'-il)-2-hidroxipropil]oxi}-4-hidroxifenil)acetamida; y ácido (2-{[(2S)-3-(5-Cloro-1'H,3H-espiro[1-benzofuran-2,4'-piperidin]-1'-il)-2-hidroxipropil]oxi}-4-fluorofenil)metansulfonico o una sal aceptable para su uso farmacéutico, un solvato osal solvatada del mismo. Reivindicacion 5: El producto farmacéutico de acuerdo con cualquiera de las reivindicaciones precedentes, caracterizado porque el agonista del receptor de glucocorticoide es budesonida. Reivindicacion 6: El productofarmacéutico de acuerdo con cualquiera de las reivindicaciones precedentes, caracterizado porque el beta2-agonista se selecciona entre cualquiera entre formoterol, indacaterol o una N-[2-(Dietilamino)etil]-N-(2-{[2-(4-hidroxi-2-oxo-2,3-dihidro-1,3-benzotiazol-7-il)etil]amino}etil)-3-[2-(1-naftiI)etoxi]propanamida o una sal de la misma, una N-[2-(Dietilamino)etil]-N-(2-{[2-(4-hidroxi-2-oxo-2,3-dihidro-1,3-benzotiazol-7-iI)etil]amino}etil)-3-[2-(3-clorofenil)etoxi]propanamida o una sal de lamisma, o una 7-[(1R)-2-({2-[(3-{[2-(2-Clorofenil)etil]amino}propil)tio]etil}amino)-1-hidroxietil]-4-hidroxi-1,3-benzotiazol-2(3H)-ona o una sal de la misma.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US89124407P | 2007-02-23 | 2007-02-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR065453A1 true AR065453A1 (es) | 2009-06-10 |
Family
ID=39710315
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080100757A AR065453A1 (es) | 2007-02-23 | 2008-02-22 | Producto farmaceutico y metodo de tratamiento |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20110124613A1 (es) |
| EP (1) | EP2120935A4 (es) |
| AR (1) | AR065453A1 (es) |
| CL (1) | CL2008000539A1 (es) |
| PE (1) | PE20090491A1 (es) |
| TW (1) | TW200848035A (es) |
| UY (1) | UY30935A1 (es) |
| WO (1) | WO2008103126A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009543860A (ja) * | 2006-07-19 | 2009-12-10 | アストラゼネカ・アクチエボラーグ | 新規三環系スピロピペリジン化合物、それらの合成およびケモカイン受容体活性モジュレーターとしてのそれらの使用 |
| UY32521A (es) * | 2009-04-03 | 2010-10-29 | Astrazeneca Ab | Combinación para emplear en el tratamiento de enfermedades respiratorias |
| WO2012163848A1 (en) | 2011-05-27 | 2012-12-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of crohn's disease |
| EP2771484A1 (en) | 2011-10-28 | 2014-09-03 | Galderma Research & Development | New leukocyte infiltrate markers for rosacea and uses thereof |
| WO2016100940A1 (en) | 2014-12-19 | 2016-06-23 | The Broad Institute, Inc. | Dopamine d2 receptor ligands |
| WO2016100823A1 (en) | 2014-12-19 | 2016-06-23 | The Broad Institute, Inc. | Dopamine d2 receptor ligands |
| GB201918692D0 (en) | 2019-12-18 | 2020-01-29 | Cambridge Entpr Ltd | Treatment and prognosis of pancreatic cancer |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2373186A (en) * | 2001-02-23 | 2002-09-18 | Astrazeneca Ab | Pharmaceutical combinations of a CCR3 antagonist and a compound which is usefulreatment of asthma, allergic disease or inflammation |
| GB0207436D0 (en) * | 2002-03-28 | 2002-05-08 | Glaxo Group Ltd | Novel compounds |
| SE0202133D0 (sv) * | 2002-07-08 | 2002-07-08 | Astrazeneca Ab | Novel compounds |
| SE0303090D0 (sv) * | 2003-11-20 | 2003-11-20 | Astrazeneca Ab | Novel compounds |
| SE0303280D0 (sv) * | 2003-12-05 | 2003-12-05 | Astrazeneca Ab | Novel compounds |
| SE0303541D0 (sv) * | 2003-12-22 | 2003-12-22 | Astrazeneca Ab | New compounds |
| TW200744612A (en) * | 2005-08-26 | 2007-12-16 | Astrazeneca Ab | New combination |
| AU2006282122A1 (en) * | 2005-08-26 | 2007-03-01 | Astrazeneca Ab | A combination of compounds, which can be used in the treatment of respiratory diseases, especially chronic obstructive pulmonary disease (COPD) and asthma |
| JP2009543860A (ja) * | 2006-07-19 | 2009-12-10 | アストラゼネカ・アクチエボラーグ | 新規三環系スピロピペリジン化合物、それらの合成およびケモカイン受容体活性モジュレーターとしてのそれらの使用 |
-
2008
- 2008-02-21 US US12/527,754 patent/US20110124613A1/en not_active Abandoned
- 2008-02-21 EP EP08712832A patent/EP2120935A4/en not_active Withdrawn
- 2008-02-21 WO PCT/SE2008/050204 patent/WO2008103126A1/en not_active Ceased
- 2008-02-22 CL CL200800539A patent/CL2008000539A1/es unknown
- 2008-02-22 UY UY30935A patent/UY30935A1/es unknown
- 2008-02-22 AR ARP080100757A patent/AR065453A1/es unknown
- 2008-02-22 PE PE2008000373A patent/PE20090491A1/es not_active Application Discontinuation
- 2008-02-22 TW TW097106287A patent/TW200848035A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| UY30935A1 (es) | 2008-09-30 |
| EP2120935A1 (en) | 2009-11-25 |
| EP2120935A4 (en) | 2011-06-22 |
| US20110124613A1 (en) | 2011-05-26 |
| PE20090491A1 (es) | 2009-05-31 |
| WO2008103126A1 (en) | 2008-08-28 |
| CL2008000539A1 (es) | 2008-10-10 |
| TW200848035A (en) | 2008-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR065453A1 (es) | Producto farmaceutico y metodo de tratamiento | |
| RU2011147232A (ru) | Производное карбоновой кислоты | |
| Islam et al. | Microtubulin binding sites as target for developing anticancer agents | |
| ES2447295T3 (es) | Métodos para el tratamiento del trastorno de déficit de atención/hiperactividad | |
| JP5934403B2 (ja) | ５，６−ジヒドロ−１ｈ−ピリジン−２−オン化合物 | |
| KR102838444B1 (ko) | 탈리도마이드 유사체 및 사용 방법 | |
| DK2552906T3 (en) | CGRP receptor antagonist | |
| RU2009126745A (ru) | Производные сульфонилфенил-2н-{1,2,4}оксадиазол-5-она, способы их получения и их применение в качестве фармацевтических средств | |
| RU2010134403A (ru) | Конденсированное производное аминодигидротиазина | |
| RU2010116759A (ru) | Пиримидиновые производные, используемые в качестве ингибиторов протеинкиназы | |
| RU2008126807A (ru) | Арил-изоксазол-4-ил-имидазо[1,2-а]пиридин, пригодный для лечения болезни альцгеймера через посредство gaba-рецепторов | |
| PE20040974A1 (es) | Compuestos de amida de acido carboxilico con efecto antagonico de la hcm, medicamentos que los contienen y procedimientos para su preparacion | |
| AR064389A1 (es) | Derivados heterociclicos de nicotinamida utiles en el tratamiento de afecciones y enfermedades alergicas y respiratorias, y composiciones farmaceuticas que los contienen. | |
| JP2005538959A5 (es) | ||
| RU2008144584A (ru) | 4,5-дигидро-[1,2,4]триазоло[4,3-f]птеридины в качестве ингибиторов протеинкиназы plk1 для лечения пролиферативных заболеваний | |
| JP2011524897A (ja) | β２−アドレナリン受容体活性の調節のための、４−ヒドロキシ−２−オキソ−２，３−ジヒドロ−１，３−ベンゾチアゾール−７−イル化合物を含む医薬組成物 | |
| AR071300A1 (es) | Compuestos; composiciones farmaceuticas en base al compuesto y uso del mismo para la manufactura de un medicamento | |
| RU2018114518A (ru) | Новые бициклические соединения в качестве двойных ингибиторов аутотаксина (atx)/карбоангидразы (ca) | |
| PE20060609A1 (es) | Derivados de quinuclidinas como antagonistas del receptor muscarinico (m3) | |
| HRP20090468T1 (hr) | Urea antagonisti p2y1 receptora korisni u liječenju trombotičkih stanja | |
| US20110183995A1 (en) | Eltoprazine for suppression of l-dopa induced dyskinesias | |
| PE20081837A1 (es) | Derivados de quinuclinidol como antagonistas de los receptores muscarinicos | |
| JP2007515476A5 (es) | ||
| RU2010107795A (ru) | Бициклические амиды для усиления глутаматергических синаптических ответов | |
| RU2006144069A (ru) | Режим приема контрацептива с антагонистом рецептора прогестерона и набор для приема |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |